✦ LIBER ✦

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

✍ Scribed by Lee, Dae Ho; Lee, Jung Shin; Kim, Sang-We; Rodrigues-Pereira, José; Han, Baohui; Song, Xiang-Qun; Wang, Jie; Kim, Hoon-Kyo; Sahoo, Tarini Prasad; Digumarti, Raghunadharao; Wang, Xin; Altug, Sedat; Orlando, Mauro

Book ID: 121288034
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 872 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.06.035

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomised phase II study of pemetrexe

A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer

✍ Dittrich, Christian; Papai-Szekely, Zsolt; Vinolas, Nuria; Sederholm, Christer; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 517 KB

A randomized, phase 2 study comparing pe

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

✍ Nabil Mubarak, Rabab Gaafar, Samir Shehata, Tarek Hashem, Dani Abigeres, Hamdy A 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 215 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB